Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China - Concepedia

Concepedia

Publication | Open Access

Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China

DOI Full Paper Access

14

Citations

9

References

2023

Year

Heng Mei, Hu Zhou, Ming Hou, Jing Sun, Lei Zhang, Jianmin Luo, Zhongxing Jiang, Ye Xu, Yajing Xu, Jun Lü,

Research and Practice in Thrombosis and Haemostasis

Abstract

Avatrombopag was efficacious and generally well tolerated in Chinese patients with chronic primary ITP, with comparable efficacy and safety to previous reports in Western patients.

References

	Year	Citations
American Society of Hematology 2019 guidelines for immune thrombocytopenia Cindy Neunert, Deirdra R. Terrell, Donald M. Arnold, Blood Advances	2019	1.2K
Updated international consensus report on the investigation and management of primary immune thrombocytopenia Drew Provan, Donald M. Arnold, James B. Bussel, Blood Advances	2019	1K
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial David J. Kuter, James B. Bussel, Roger M. Lyons, The Lancet ThrombopoiesisThrombosisAutoimmune DiseaseBlood PlateletImmunology	2008	851
Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia Wojciech Jurczak, Krzysztof Chojnowski, Katarzyna Krawczyk, British Journal of Haematology	2018	204
A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia James B. Bussel, David J. Kuter, Louis M. Aledort, Blood	2014	161
Multicentre, randomised phase<scp>III</scp>study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia Renchi Yang, Junmin Li, Jie Jin, British Journal of Haematology	2016	77
A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia Heng Mei, Xiaofan Liu, Yan Li, Journal of Hematology & Oncology	2021	66
[Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020)]. PubMed ThrombopoiesisImmunohematologyThrombosisAutoimmune DiseaseBlood Platelet	2020	51
A multicentre double‐blind, double‐dummy, randomised study of recombinant human thrombopoietin <i>versus</i> eltrombopag in the treatment of immune thrombocytopenia in Chinese adult patients Heng Mei, Min Xu, Guolin Yuan, British Journal of Haematology	2021	24

Page 1